Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Which genomic test do you choose for a patient with favorable intermediate prostate cancer trying to decide between active surveillance and treatment?
Answer from: Radiation Oncologist at Academic Institution
Decipher.
Sign in or Register to read more
22021
Related Questions
When treating inguinal lymph nodes in the setting of pelvic RT, what is your preferred setup in order to minimize dose to the penis?
How do you dose or sequence therapy to overcome radioresistance from oligometastatic disease from RCC?
How do you manage favorable intermediate risk prostate cancer patients that have a PIRADS 5 lesion that was most-likely missed in the template biopsy?
Would you irradiate the elective pelvis of a patient with high risk prostate cancer in the setting of osteoporosis and sacral insufficiency fractures?
Would you dose escalate for prostate cancer extending to the penile bulb, towards the urethra, and close to anorectal junction?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
For patients with metastatic RCC and gross hematuria from the primary tumor, what palliative radiation regimen would you recommend to help control the bleeding?
Do you include the prostate when treating bladder cancer?
Would you offer salvage radiation for prostate bed recurrence on PSMA PET in a patient with limited bone mets?
In post-prostatectomy patients where urinary continence is never achieved, how and when would you plan RT when it is clinically indicated?